Literature DB >> 17414751

Poorly versus moderately differentiated hepatocellular carcinoma: vascularity assessment by computed tomographic hepatic angiography in correlation with histologically counted number of unpaired arteries.

Yoshiki Asayama1, Kengo Yoshimitsu, Hiroyuki Irie, Yunosuke Nishihara, Shinichi Aishima, Tsuyoshi Tajima, Masakazu Hirakawa, Kousei Ishigami, Daisuke Kakihara, Akinobu Taketomi, Hiroshi Honda.   

Abstract

PURPOSE: To determine the vascularity of moderately and poorly differentiated hepatocellular carcinoma (mHCC and pHCC, respectively) as observed on and depicted by computed tomography during hepatic angiography and to perform pathological correlation.
MATERIALS AND METHODS: Eighty-seven consecutive patients with 89 hepatocellular carcinomas (61 mHCCs and 28 pHCCs) were surgically resected in our hospital. The degree of contrast enhancement on computed tomography during hepatic angiography of the tumors was classified into high attenuation (H), isoattenuation (I), and low attenuation (L). We also examined hepatocellular carcinomas measuring less than 4 cm in diameter. Pathologically, the number of unpaired arteries in the tumors was determined (x200 magnification).
RESULTS: The number of mHCC and pHCC in each degree of enhancement (H/I/L) was 59:1:1 and 19:6:3, respectively. The number of mHCC and pHCC measuring less than 4 cm without portal invasion was 48 and 15, respectively; the number of these tumors in each degree of enhancement (H/I/L) was 47:1:0 and 11:3:1, respectively. The mean number of unpaired arteries was 8.9 +/- 4.4 in mHCC and 5.2 +/- 4.3 in pHCC, respectively. All results were statistically significant (P < 0.01).
CONCLUSIONS: Our results indicated that the arterial blood supply of pHCC was lower than that of mHCC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17414751     DOI: 10.1097/01.rct.0000236417.82395.57

Source DB:  PubMed          Journal:  J Comput Assist Tomogr        ISSN: 0363-8715            Impact factor:   1.826


  10 in total

Review 1.  CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects.

Authors:  Jin-Young Choi; Jeong-Min Lee; Claude B Sirlin
Journal:  Radiology       Date:  2014-09       Impact factor: 11.105

2.  Preliminary study of apparent diffusion coefficient assessment after ion beam therapy for hepatocellular carcinoma.

Authors:  Masayuki Kanamoto; Tosiaki Miyati; Kazuki Terashima; Daisaku Suga; Nobukazu Fuwa
Journal:  Radiol Phys Technol       Date:  2016-04-07

Review 3.  Joint Consensus Statement of the Indian National Association for Study of the Liver and Indian Radiological and Imaging Association for the Diagnosis and Imaging of Hepatocellular Carcinoma Incorporating Liver Imaging Reporting and Data System.

Authors:  Sonal Krishan; Radha K Dhiman; Navin Kalra; Raju Sharma; Sanjay S Baijal; Anil Arora; Ajay Gulati; Anu Eapan; Ashish Verma; Shyam Keshava; Amar Mukund; S Deva; Ravi Chaudhary; Karthick Ganesan; Sunil Taneja; Ujjwal Gorsi; Shivanand Gamanagatti; Kumble S Madhusudan; Pankaj Puri; Shallini Govil; Manav Wadhavan; Sanjiv Saigal; Ashish Kumar; Shallini Thapar; Ajay Duseja; Neeraj Saraf; Anubhav Khandelwal; Sumit Mukhopadyay; Ajay Gulati; Nitin Shetty; Nipun Verma
Journal:  J Clin Exp Hepatol       Date:  2019-08-06

4.  Diffuse intrahepatic recurrence after percutaneous radiofrequency ablation for solitary and small hepatocellular carcinoma.

Authors:  Yoshiyuki Mori; Hideyuki Tamai; Naoki Shingaki; Kosaku Moribata; Tatsuya Shiraki; Hisanobu Deguchi; Kazuki Ueda; Shotaro Enomoto; Hiroto Magari; Izumi Inoue; Takao Maekita; Mikitaka Iguchi; Kimihiko Yanaoka; Masashi Oka; Masao Ichinose
Journal:  Hepatol Int       Date:  2009-04-29       Impact factor: 6.047

5.  Deep Learning Predicts Overall Survival of Patients With Unresectable Hepatocellular Carcinoma Treated by Transarterial Chemoembolization Plus Sorafenib.

Authors:  Lei Zhang; Wei Xia; Zhi-Ping Yan; Jun-Hui Sun; Bin-Yan Zhong; Zhong-Heng Hou; Min-Jie Yang; Guan-Hui Zhou; Wan-Sheng Wang; Xing-Yu Zhao; Jun-Ming Jian; Peng Huang; Rui Zhang; Shen Zhang; Jia-Yi Zhang; Zhi Li; Xiao-Li Zhu; Xin Gao; Cai-Fang Ni
Journal:  Front Oncol       Date:  2020-09-30       Impact factor: 6.244

6.  DCE-MRI of hepatocellular carcinoma: perfusion quantification with Tofts model versus shutter-speed model--initial experience.

Authors:  Guido H Jajamovich; Wei Huang; Cecilia Besa; Xin Li; Aneela Afzal; Hadrien A Dyvorne; Bachir Taouli
Journal:  MAGMA       Date:  2015-12-08       Impact factor: 2.310

7.  Relationship between microvessel count and post-hepatectomy survival in patients with hepatocellular carcinoma.

Authors:  Atsushi Nanashima; Toshiyuki Nakayama; Yorihisa Sumida; Takafumi Abo; Hiroaki Takeshita; Kenichirou Shibata; Shigekazu Hidaka; Terumitsu Sawai; Toru Yasutake; Takeshi Nagayasu
Journal:  World J Gastroenterol       Date:  2008-08-21       Impact factor: 5.742

Review 8.  Transarterial chemoembolization using iodized oil for unresectable hepatocellular carcinoma: perspective from multistep hepatocarcinogenesis.

Authors:  Kengo Yoshimitsu
Journal:  Hepat Med       Date:  2014-07-03

9.  Liver MRI and clinical findings to predict response after drug eluting bead transarterial chemoembolization in hepatocellular carcinoma.

Authors:  Jeong Yeop Lee; Byung Chan Lee; Hyoung Ook Kim; Suk Hee Heo; Sang Soo Shin; Yong Yeon Jeong
Journal:  Sci Rep       Date:  2021-12-15       Impact factor: 4.379

10.  Predictive imaging for tumor response to drug-eluting microsphere transarterial chemoembolization in patients with BCLC-C advanced hepatocellular carcinoma.

Authors:  Kai-Hsiang Chang; Zhen-An Hwang; Ping-Ying Chang; Hsuan-Hwai Lin; Yu-Lueng Shih; Wei-Chou Chang; Guo-Shu Huang; Hsian-He Hsu
Journal:  Sci Rep       Date:  2019-12-27       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.